R&D Immune mediation, B-cell depletion, and female leadership – ... In a new pharmaphorum podcast, Aoife Brennan, CEO of Climb Bio, discusses the treatment of immune-mediated diseases.
R&D Bridging science and care: Advancing biomedical innovation As public funding becomes more uncertain, lab and clinical services professionals are increasingly being called on to help.
R&D Medicine’s blind spot: How clinical trials are failing women From insulin to immunotherapies, clinical trials have powered some of the most important medical breakthroughs of our time.
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
R&D What to do when your grant application fails All hope should not be lost and an unsuccessful application doesn’t always mark the end of the road.
R&D Post-hype, pre-value: The real AI-pharma shift starts now The first era of AI in pharma was built on potential. This next era will be built on proof, reinforcing even greater potential.
News FDA clears at-home start dose for Alzheimer's drug Leqembi The FDA has cleared Eisai and Biogen's Leqembi Iqlik subcutaneous injection as a starting dose, removing the need for regular infusion clinic visits.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
